{"id":"ce328350273d","type":"article","url":"https://hartvaat.nl/2025/01/01/aficamten-bij-obstructieve-hcm-multidomeinanalyse-van-maple-hcm/","title":"Aficamten bij obstructieve HCM: multidomeinanalyse van MAPLE-HCM","title_en":"Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","aficamten","cardio-renaal-metabool","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","iaso-dcm","immunoadsorptie","laminopathie","mavacamten","myocardinfarct","summit-trial","ventrikelfibrilleren","vrouwen"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725100685?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109725100685?dgcid=rss_sd_all","authors":["Andrew Wang","Pablo Garcia-Pavia","Ahmad Masri","Bela Merkely","Michael E. Nassif","Maria Luisa Peña-Peña","Roberto Barriales-Villa","Ozlem Bilen","Melissa Burroughs","Brian L. Claggett"],"significance":8,"published":"2026-03-14","source_date":"2025-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"This multidomain patient-level analysis of the MAPLE-HCM trial evaluated aficamten across multiple outcome domains in obstructive hypertrophic cardiomyopathy, providing comprehensive evidence on the clinical benefit of cardiac myosin inhibition.","created":"2026-07-03T10:32:34Z","updated":"2026-07-03T18:39:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze JACC-publicatie presenteert een multidomein patiëntanalyse van de MAPLE-HCM trial met aficamten bij obstructieve hypertrofische cardiomyopathie. De analyse combineert hemodynamische, functionele en patiëntgerapporteerde uitkomsten en toont consistente voordelen van aficamten over meerdere eindpunten.","abstract_original":"Publication date: 3 March 2026Source: JACC, Volume 87, Issue 8"}